Serum miRNA-126 level and vasculogenic mimicry in patients with hepatitis B hepatocellular carcinoma

SHEN Hong; CHENG Liya; ZONG Chunhui; MA Cheng; ZHAO Dongyu

PDF(874 KB)

Medical Journal of the Chinese People Armed Police Forces ›› 2021, Vol. 32 ›› Issue (5) : 378-381.

ORIGINAL ARTICLES

Serum miRNA-126 level and vasculogenic mimicry in patients with hepatitis B hepatocellular carcinoma

SHEN Hong¹, CHENG Liya¹, ZONG Chunhui², MA Cheng¹, ZHAO Dongyu¹

Author information +

History +

Abstract

Objective To investigate the relationship between miRNA-126 and vasculogenic mimicry (VM) in patients with hepatitis B hepatocellular carcinoma (HCC).Methods A total of 183 patients with hepatitis B related HCC in BCLC stage I-IIa who underwent radical hepatectomy were selected as the research objects from October 2016 to October 2019. At the same time, 183 healthy people were randomly selected as the control group. The expression of miRNA-126 in serum was detected by PCR. Then, HE staining and CD34-PAS double staining were used to analyze the influencing factors of VM positive in HCC patients. The ROC curve for predicting VM was constructed.Results The expression of serum miRNA-126 in HCC patients was lower than that in control group. Among HCC patients, 74 cases were VM positive and 109 cases were VM negative. The result of logistic regression analysis showed that low expression of miRNA-126(P=0.008), tumor size (P=0.001) and increased AFP (P=0.000) were associated with VM. miRNA-126 has a high predictive value for VM positive, AUC=0.869(95%CI:0.815-0.924). Conclusions The expression of miRNA-126 can be used as a noninvasive marker of HCC.

Key words

hepatocellular carcinoma / microRNA-126 / vasculogenic mimicry / correlation

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

SHEN Hong, CHENG Liya, ZONG Chunhui, MA Cheng, ZHAO Dongyu. Serum miRNA-126 level and vasculogenic mimicry in patients with hepatitis B hepatocellular carcinoma[J]. Medical Journal of the Chinese People Armed Police Forces. 2021, 32(5): 378-381

References

[1] 中华预防医学会肿瘤预防与控制专业委员会感染相关肿瘤防控学组, 中华预防医学会慢病预防与控制分会, 中华预防医学会健康传播分会. 中国肝癌一级预防专家共识(2018)[J]. 中华预防医学杂志, 2019, 53(1):36-44.
[2] 陶明珠, 胡书娅, 郭庆喜,等. 肝细胞癌组织中肿瘤相关成纤维细胞与血管生成拟态的相关性及临床意义[J]. 现代肿瘤医学, 2019, 27(23):111-114.
[3] 李杰, 马晓洁, 杜小波, 等. 原发性肝癌血管生成拟态表达对患者预后的影响[J]. 实用医院临床杂志, 2014, 11(2):102-106.
[4] Li Z, Lei Z, Xia Y, et al. Association of preoperative antiviral treatment with incidences of microvascular invasion and early tumor recurrence in hepatitis B virus-related epatocellular carcinoma[J].JAMA Surg,2018,153(10):e182721.
[5] 何婷,屈波,任贵兵.miRNA-1-3p在肝脏肿瘤细胞的增殖和迁移中的作用研究[J].现代消化及介入诊疗,2020,25(6):728-734.
[6] Wei F, Ma C, Zhou T, et al. Exosomes derived from gemcitabine-resistant cells transfer malignant phenotypic traits via delivery of miRNA-222-3p[J].Mol Cancer, 2017,16(1):132.
[7] 邹燕, 肖凯强, 何雪梅,等. miRNAs与血管新生关系的研究进展[J]. 山东医药, 2018, 58(10):106-109.
[8] 周轶冰. 肝细胞癌患者血清中microRNA-21和microRNA-126的表达水平及临床意义[J]. 中国现代医药杂志, 2018, 20(4):53-55.
[9] 吴共发, 邱丽浈, 黄绮亭,等. 结直肠癌微血管、淋巴管以及血管生成拟态与其临床病理特征的关系[J]. 海南医学, 2019, 30(9):7-10.
[10] 罗昕, 徐铭益. microRNA-27a在多种肝脏疾病发生发展中的作用机制[J].临床肝胆病杂志,2020,36(7):1666-1668.
[11] Sartorius K, Makarova J, Sartorius B, et al. The regulatory role of microRNA in hepatitis-B virus-associated hepatocellular carcinoma (HBV-HCC) Pathogenesis[J].Cells, 2019, 8(12):1504.
[12] Liao X, Zhu G, Huang R, et al. Identification of potential prognostic microRNA biomarkers for predicting survival in patients with hepatocellular carcinoma[J].Cancer Manag Res, 2018,10,787-803.
[13] Hu M H, Ma C Y, Wang X M, et al. MicroRNA-126 inhibits tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression[J].Oncotarget, 2016,7(41):66922-66934.
[14] Bao J, Yu Y, Chen J, et al. MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway[J].Cell Death Dis, 2018,9(10):1045.
[15] 张红, 朱民高, 韩雪飞,等. 血管生成拟态在肝癌转移中的作用机制研究进展[J]. 中华实验外科杂志, 2014, 31(3):684-685.
[16] Du C, Lv Z, Cao L, et al. MiR-126-3p suppresses tumor metastasis and angiogenesis of hepatocellular carcinoma by targeting LRP6 and PIK3R2[J].J Transl Med, 2014,12:259.
[17] 秦巧红, 任琛琛, 刘星烁. MiR-126,血管内皮生长因子的表达与微血管密度在上皮性卵巢癌组织中的变化[J]. 肿瘤基础与临床, 2017, 30(4):277-280.
[18] 李勋光, 万珙善, 梁艳霞, 等. MicroRNA-126抗肺癌A549裸鼠移植瘤生长的实验研究[J]. 中华肿瘤防治杂志, 2015,(B11):153-155.
[19] 孟令娇, 丁平安, 刘思桦,等. 微RNA-1299在三阴性乳腺癌中的表达及其对乳腺癌细胞迁移和侵袭的影响[J]. 肿瘤, 2018, 38(11):1022-1030.
[20] 唐夏莉, 焦德敏, 陈君,等. miRNA-126对肺癌A549细胞的增殖,迁移,侵袭及EGFR/AKT/mTOR信号通路的影响[J]. 中国病理生理杂志, 2016, 32(3):458-463.